Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment-Reference-Cited by-同舟云学术

Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment

Published:2019-04-25 Issue:2 Volume:143 Page:241-249
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Wu Adela^ORCID,Maxwell Russell,Xia Yuanxuan,Cardarelli Pina,Oyasu Miho,Belcaid Zineb,Kim Eileen,Hung Alice,Luksik Andrew S.,Garzon-Muvdi Tomas,Jackson Christopher M.,Mathios Dimitrios,Theodros Debebe,Cogswell John,Brem Henry,Pardoll Drew M.,Lim Michael

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Clinical Neurology,Neurology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11060-019-03172-5.pdf

Reference33 articles.

1. Theeler BJ, Gilbert MR (2015) Advances in the treatment of newly diagnosed glioblastoma. BMC Med 13(1):293. https://doi.org/10.1186/s12916-015-0536-8

2. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330

3. Weller M, Butowski N, Tran DD et al (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18(10):1373–1385. https://doi.org/10.1016/S1470-2045(17)30517-X

4. Reardon DA, Omuro A, Brandes AA et al (2017) Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro Oncol 19(Suppl 3):iii21

5. Kim JE, Patel MA, Mangraviti A et al (2017) Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res 23(1):124–136. https://doi.org/10.1158/1078-0432.CCR-15-1535

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape;Frontiers in Immunology;2024-09-13

2. Machine learning models predict the immunotherapy response in tumor based on DNA methylation;2024-08-29

3. Integrin blocking peptide reverses immunosuppression in experimental gliomas and improves anti-PD-1 therapy outcome;2024-08-08

4. Glioma stem cells remodel immunotolerant microenvironment in GBM and are associated with therapeutic advancements;Cancer Biomarkers;2024-08-04

5. CXCR7 activation evokes the anti-PD-L1 antibody against glioblastoma by remodeling CXCL12-mediated immunity;Cell Death & Disease;2024-06-19